1-(4-methylbenzenesulfonyl)-3-{octahydrocyclopenta[c]pyrrol-2-yl}urea

• ChemBase编号: 991
• 分子式: C15H21N3O3S
• 平均质量: 323.41054
• 单一同位素质量: 323.13036255
• SMILES: S(=O)(=O)(NC(=O)NN1CC2C(CCC2)C1)c1ccc(cc1)C
• Canonical SMILES: O=C(NS(=O)(=O)c1ccc(cc1)C)NN1CC2C(C1)CCC2
• InChI: InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
• InChIKey: BOVGTQGAOIONJV-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 1-(4-methylbenzenesulfonyl)-3-{octahydrocyclopenta[c]pyrrol-2-yl}urea
• IUPAC传统名: 3-{hexahydro-1H-cyclopenta[c]pyrrol-2-yl}-1-(4-methylbenzenesulfonyl)urea; gliclazide; 1-(4-methylbenzenesulfonyl)-3-{octahydrocyclopenta[c]pyrrol-2-yl}urea
• 商标名: Diamicron; Glimicron; Nordialex; Diamicron MR; Mylan-Gliclazide; PMS-Gliclazide
• 别名: N-[[(Hexahydrocylopenta[c]pyrrol-2(1H)-yl]amino]carbonyl]-4-methylbenzenesulfonamide; Glimicron; Nordialex; S-1702; 1-(3-Azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea; 1-(Hexahydrocyclopenta(c)pyrrol-2(1H)-yl)-3-(p-tolylsulfonyl)urea; Gliclazida [INN-Spanish]; Gliclazidum [INN-Latin]; N-(4-Methylbenzenesulfonyl)-N'-(3-azabicyclo(3.3.0)oct-3-yl)urea; Gliclazide; Diamicron; 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea; Gliclazide; N-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)carbamoyl)-4-methylbenzenesulfonamide; Diabrezide; Glyclazide; Unava

登记号

• CAS号: 21187-98-4
• EC号: 244-260-5
• MDL号: MFCD00409893
• PubChem SID: 46505475; 160964454; 24895090
• PubChem CID: 3475

理论计算性质

JChem

• Acid pKa: 4.070456
• 质子受体: 4
• 质子供体: 2
• LogD (pH = 5.5): 0.89702356
• LogD (pH = 7.4): 0.7922661
• Log P: 1.733641
• 摩尔折射率: 83.8761 cm^3
• 极化性: 33.30756 Å^3
• 极化表面积: 78.51 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.52
• LOG S: -3.23
• 溶解度: 1.90e-01 g/l

分子性质

理化性质

• 溶解度: Chloroform; methylene chloride: soluble
• 外观: white powder; White Solid
• 熔点: 163-169 °C(lit.); 164-166°C
• 疏水性(logP): 2.6

安全信息

• 保存条件: -20°C; -20°C Freezer
• RTECS编号: YT4500000
• 德国WGK号: 2
• 个人保护装置: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter

药理学性质

• 相关基因信息: human ... KCNJ1(3758)
• 生物活性机理: Appears to enhance glucose stimulated insulin secretion at a submaximally stimulating blood-glucose level

产品相关信息

• 纯度: ≥98%
• 成盐信息: Free Base
• 应用领域: Antidiabetic; Oral antihyperglycaemic agent
• Empirical Formula (Hill Notation): C15H21N3O3S

详细说明

DrugBank - DB01120

• Drug Groups: approved
• Description: Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70%) and feces (10-20%).
• Indication: For the treatment of NIDDM in conjunction with diet and exercise.
• Pharmacology: Gliclazide is a second generation sulphonylurea which acts as a hypoglycemic agent. It stimulates β cells of the islet of Langerhans in the pancreas to release insulin. It also enhances peripheral insulin sensitivity. Overall, it potentiates insulin release and improves insulin dynamics.
• Toxicity: LD₅₀=3000 mg/kg (orally in mice). Gliclazide and its metabolites may accumulate in those with severe hepatic and/or renal dysfunction. Symptoms of hypoglycemia include: dizziness, lack of energy, drowsiness, headache and sweating.
• Affected Organisms: Humans and other mammals
• Biotransformation: Extensively metabolized in the liver. Less than 1% of the orally administered dose appears unchanged in the urine. Metabolites include oxidized and hydroxylated derivates, as well as glucuronic acid conjugates.
• Absorption: Rapidly and well absorbed but may have wide inter- and intra-individual variability. Peak plasma concentrations occur within 4-6 hours of oral administration.
• Half Life: 10.4 hours. Duration of action is 10-24 hours.
• Protein Binding: 94%, highly bound to plasma proteins
• Elimination: Metabolites and conjugates are eliminated primarily by the kidneys (60-70%) and also in the feces (10-20%).
• External Links: Wikipedia

Selleck Chemicals - S2601

Research Area: Metabolic Disease
Biological Activity:
Gliclazide (Diamicron) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 ± 30 nM. Gliclazide (Diamicron) binds to sulfonylurea receptors on the surface of the Beta islet cells found in the pancreas. This binding effectively closes the K+ ion channels. This decreases the efflux of potassium from the cell which leads to the depolarization of the cell. This causes voltage dependent Ca2+ ion channels to open increasing the Ca2+ influx. The calcium can then bind to and activate calmodulin which in turn leads to exocystosis of insulin vesicles leading to insulin release. Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset or adult type. Gliclazide (Diamicron) is used when diabetes cannot be controlled by proper dietary management and exercise or when insulin therapy is not appropriate. [1][2][3]References on Gliclazide (Diamicron)[1] Diabetologia. , 2001 Aug, 44(8):1019-25[2] http://en.wikipedia.org/wiki/Gliclazide, , [3] Diabetes., 2009 Oct, 58(10):2419-24

Sigma Aldrich - G2167

Application
Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM).
Biochem/physiol Actions
Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases

Toronto Research Chemicals - G409875

A sulfonylurea hypoglycemic agent. Used as an antidiabetic.

参考文献

• Hamming KS et al. Diabetes. 2009 Oct;58(10):2419-24.
• Duhault, J., et al.: Arzneimittel-Forsch., 22, 1686 (1972)
• Holmes, B., et al.: Drugs, 27, 301 (1972)
• U.K. Pat., 1968, 1 153 982; CA, 70, 47290e, (synth)
• Duhault, J. et al., Arzneim.-Forsch., 1972, 22, 1682, (pharmacol, tox)
• Keen, H. et al., Int. Congr. Symp. Ser. R. Soc. Med., No. 20, 1980
• Holmes, B. et al., Drugs, 1984, 27, 301, (rev)
• Oida, T. et al., Xenobiotica, 1985, 15, 87, (metab)
• Palmer, K.J. et al., Drugs, 1993, 46, 92, (rev)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 279
• Winters, C.S. et al., J. Pharm. Sci., 1994, 83, 300, (cmr, cryst struct)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 7th edn., Akademie-Verlag, 1994, 4770, (synonyms)
• Parvez, M. et al., Acta Cryst. C, 1999, 55, 74-75, (cryst struct)
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, DBL700